drugset / Trial / NCT02449018

A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251

NCT02449018

Phase 2 Completed 92 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupTriple-blindTreatment

Summary

To evaluate the efficacy, safety and tolerability of multiple doses of QBW251 vs placebo administered orally, on airway function, lung volume, and quality of life in patients with chronic obstructive pulmonary disease (COPD)

Timeline

Start
2015-04-30
Primary completion
2016-12-27
Completion
2017-01-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Icenticaftor Small molecule Oral